Matinas BioPharma Holdings, Inc.
MTNB
Rank in Stocks
#33458
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical... Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Share Price
$1.24
Last synced: 2026-11-09
Market Cap
$529.58K
Change (1 day)
4.20%
Change (1 year)
3.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Matinas BioPharma Holdings, Inc. (MTNB)
Category
Healthcare
EPS for Matinas BioPharma Holdings, Inc. (MTNB)
EPS as of June 2026 TTM: $-18.15
According to Matinas BioPharma Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $-18.15. At the end of 2025 the company had an EPS of $-30.00, an increase over its 2024 EPS of $-74.70.
EPS history for Matinas BioPharma Holdings, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-18.15 | -39.50% |
| 2025 | $-30.00 | -59.84% |
| 2024 | $-74.70 | -5.68% |
| 2023 | $-79.20 | 76.00% |
| 2022 | $-45.00 | -40.48% |
| 2021 | $-75.60 | -3.63% |
| 2020 | $-78.45 | -2.61% |
| 2019 | $-80.55 | -25.21% |
| 2018 | $-107.70 | -16.12% |
| 2017 | $-128.40 | 29.89% |
| 2016 | $-98.85 | -25.70% |
| 2015 | $-133.05 | -44.32% |
| 2014 | $-238.95 | 174.66% |
| 2013 | $-87.00 | 900.00% |
| 2012 | $-8.70 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -186.28% |
US
|
|
| $-7.07 | -61.05% |
US
|
|
| $-5.29 | -70.85% |
AU
|
|
| $12.88 | -170.96% |
BE
|
|
| $21.56 | -218.79% |
NL
|
Questions about Matinas BioPharma Holdings, Inc.'s earnings per share (EPS)
What is Matinas BioPharma Holdings, Inc.'s earnings per share (EPS)?
Matinas BioPharma Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $-18.15, as of Jun 2026.
What was Matinas BioPharma Holdings, Inc.'s earnings per share (EPS) in 2025?
In 2025, Matinas BioPharma Holdings, Inc.'s earnings per share (EPS) was $-30.00, compared with $-74.70 in 2024.
How has Matinas BioPharma Holdings, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Matinas BioPharma Holdings, Inc.'s earnings per share (EPS) was highest in 2025 ($-30.00) and lowest in 2023 ($-79.20).
How does Matinas BioPharma Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Matinas BioPharma Holdings, Inc.'s earnings per share (EPS) ($-18.15) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.